Tags

Type your tag names separated by a space and hit enter

Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Vaccine. 2005 Mar 18; 23(17-18):2342-8.V

Abstract

The health and economic costs and benefits of vaccinating a cohort of 60,000 children born in Catalonia in the year 2000 with the pneumococcal 7-valent conjugated vaccine were compared with the alternative of not implementing the vaccination programme. The time horizon fixed for the programme was 10 years for invasive disease, 2 years for all episodes of pneumonia and otitis media and 3.5 years for the placement of tympanostomy tubes. In the base case (incidence rate of invasive disease of 160 per 100,000 and price of the vaccine 50 euros) the net present value was negative, both from the societal perspective (-5.1million euros) and from the provider's perspective (-9.2million euros). The benefit-cost ratio was 0.59 euros from the societal perspective. The cost per disability adjusted life year (DALY) gained was 44,307 euros from the societal perspective and 80,291 euros from the provider's perspective.

Authors+Show Affiliations

General-Directorate of Public Health, Department of Health, Generalitat of Catalonia, Travessera de les Corts, 131-159, 08028 Barcelona, Spain. e.navas@gencat.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15755625

Citation

Navas, E, et al. "Cost-benefit and Cost-effectiveness of the Incorporation of the Pneumococcal 7-valent Conjugated Vaccine in the Routine Vaccination Schedule of Catalonia (Spain)." Vaccine, vol. 23, no. 17-18, 2005, pp. 2342-8.
Navas E, Salleras L, Gisbert R, et al. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine. 2005;23(17-18):2342-8.
Navas, E., Salleras, L., Gisbert, R., Domínguez, A., Timoner, E., Ibáñez, D., & Prat, A. (2005). Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine, 23(17-18), 2342-8.
Navas E, et al. Cost-benefit and Cost-effectiveness of the Incorporation of the Pneumococcal 7-valent Conjugated Vaccine in the Routine Vaccination Schedule of Catalonia (Spain). Vaccine. 2005 Mar 18;23(17-18):2342-8. PubMed PMID: 15755625.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). AU - Navas,E, AU - Salleras,L, AU - Gisbert,R, AU - Domínguez,A, AU - Timoner,E, AU - Ibáñez,D, AU - Prat,A, PY - 2005/3/10/pubmed PY - 2005/5/19/medline PY - 2005/3/10/entrez SP - 2342 EP - 8 JF - Vaccine JO - Vaccine VL - 23 IS - 17-18 N2 - The health and economic costs and benefits of vaccinating a cohort of 60,000 children born in Catalonia in the year 2000 with the pneumococcal 7-valent conjugated vaccine were compared with the alternative of not implementing the vaccination programme. The time horizon fixed for the programme was 10 years for invasive disease, 2 years for all episodes of pneumonia and otitis media and 3.5 years for the placement of tympanostomy tubes. In the base case (incidence rate of invasive disease of 160 per 100,000 and price of the vaccine 50 euros) the net present value was negative, both from the societal perspective (-5.1million euros) and from the provider's perspective (-9.2million euros). The benefit-cost ratio was 0.59 euros from the societal perspective. The cost per disability adjusted life year (DALY) gained was 44,307 euros from the societal perspective and 80,291 euros from the provider's perspective. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/15755625/Cost_benefit_and_cost_effectiveness_of_the_incorporation_of_the_pneumococcal_7_valent_conjugated_vaccine_in_the_routine_vaccination_schedule_of_Catalonia__Spain__ DB - PRIME DP - Unbound Medicine ER -